If we are serious in this continent, we need to manufacture what we need.
For only the third time in recorded history, the Bundibugyo variant of Ebola has emerged among human populations — this time crossing borders between Congo and Uganda, reaching capital cities, and claiming 88 lives before the world was formally alerted. The World Health Organization's declaration of a global health emergency is both a call to collective action and a mirror held up to the enduring inequities of global medicine, where rare diseases afflicting poor nations struggle to attract the investment that might save lives. What unfolds now is not merely a public health crisis but a reckoning with how the world decides whose suffering warrants a cure.
- Fifty people died before health authorities even learned the outbreak existed — the virus had weeks to move invisibly through conflict-fractured communities before a social media post broke the silence.
- The Bundibugyo variant has no approved vaccine and no approved treatment, leaving doctors with almost nothing to offer patients in a region already torn apart by militant violence and mass displacement.
- A confirmed case in Kinshasa — over 600 miles from the outbreak's origin — and cases in Uganda's capital Kampala signal that containment is already under severe strain across international borders.
- The WHO's emergency declaration is designed to unlock global resources, but the 2024 mpox experience cast a long shadow: declarations do not automatically move diagnostics, medicines, or vaccines to the places that need them.
- Africa CDC's director is pushing hard for the continent to build its own manufacturing capacity, framing dependency on foreign pharmaceutical decisions as an existential vulnerability the current crisis has once again exposed.
On Sunday, the World Health Organization declared the Ebola outbreak spreading across Congo and Uganda a public health emergency of international concern — more than 300 suspected cases, 88 deaths, and a virus for which no approved treatment or vaccine exists.
The culprit is the Bundibugyo variant, one of Ebola's rarest forms, having surfaced only twice before: in Uganda in 2007–2008 and in Congo in 2012. This third emergence is the most alarming yet. The first confirmed case appeared on April 24 in Ituri province, when a 59-year-old man fell ill and died within days. By the time authorities were alerted — through a social media post on May 5 — fifty people had already died. The delay gave the virus weeks to spread unchecked through communities, transmitted through blood, vomit, and other bodily fluids. At least four healthcare workers died while treating patients.
The outbreak's geography makes containment deeply difficult. Ituri province sits near the borders of Uganda and South Sudan, a region shattered by conflict with militant groups, some linked to the Islamic State. Constant cross-border movement driven by mining and displacement has carried the virus outward. A confirmed case has now appeared in Kinshasa, roughly 620 miles away, and cases have surfaced in Uganda's capital Kampala and in the densely populated North Kivu province.
The WHO's declaration is intended to mobilize international resources and coordination, though officials were careful to note this does not rise to the level of a pandemic emergency. The concern is whether the declaration will translate into real action. When mpox outbreaks were declared a global emergency in 2024, the flow of diagnostics and medicines to affected African nations remained frustratingly slow.
At the heart of the crisis is a market failure: pharmaceutical companies have little financial incentive to develop treatments for a rare virus that primarily threatens poor nations. Four potential therapeutics are under consideration, but none are approved and no vaccine is in active development. Africa CDC Director-General Jean Kaseya put the structural problem plainly — the continent cannot keep waiting for others to decide what gets made. Whether that conviction can be turned into manufacturing capacity before this outbreak outpaces containment remains the urgent, unanswered question.
On Sunday, the World Health Organization formally declared the Ebola outbreak spreading across Congo and Uganda a public health emergency of international concern. The numbers were stark: more than 300 suspected cases, 88 deaths, and a virus for which medicine has no approved treatment or vaccine.
The outbreak is caused by the Bundibugyo virus, a rare variant of Ebola that has surfaced only twice before in recorded history. The first appearance came in 2007 and 2008 in Uganda's Bundibugyo district, where it infected 149 people and killed 37. A second outbreak occurred in 2012 in the Congolese town of Isiro, claiming 57 cases and 29 lives. This third emergence marks a troubling return of a pathogen that remains poorly understood and entirely without therapeutic options.
What makes the current situation particularly alarming is how long the virus circulated before anyone sounded an alarm. The earliest confirmed case appeared on April 24, when a 59-year-old man developed symptoms in Ituri province. He died three days later. By the time health authorities learned of the outbreak through social media on May 5, fifty people had already died. The delay meant the virus had weeks to move through communities unchecked, spreading through bodily fluids—blood, vomit, semen—with no one tracking its path or isolating the infected. At least four healthcare workers contracted the disease while treating patients, a grim reminder of how easily the virus moves through those trying to stop it.
The geography of the outbreak compounds the challenge. The epicenter lies in Ituri province in eastern Congo, near the borders with Uganda and South Sudan, a region fractured by violent conflict with militant groups, some backed by the Islamic State. Population movement driven by mining operations and displacement from fighting means people cross borders constantly, carrying the virus with them. A laboratory-confirmed case has now appeared in Kinshasa, Congo's capital, roughly 620 miles from Ituri—evidence that the outbreak has already begun spreading far beyond its origin point. Cases have also surfaced in Uganda's capital, Kampala, and in North Kivu province, one of Congo's most densely populated regions.
The WHO's declaration is meant to mobilize the world. It signals that the outbreak is serious, poses a risk of international spread, and demands a coordinated global response. Yet the organization was careful to note this does not meet the threshold of a pandemic emergency like COVID-19, and it advised against closing international borders. Still, the declaration carries weight: it is meant to push donor agencies and wealthy nations to act. The problem is that history suggests such declarations often fail to deliver. When the WHO declared mpox outbreaks in Africa a global emergency in 2024, experts noted the declaration did little to accelerate the flow of diagnostic tests, medicines, and vaccines to the countries that needed them most.
The absence of treatment options for Bundibugyo is the core crisis. Pharmaceutical companies are considering four potential therapeutics, but none are approved. No vaccine is being actively developed. The fundamental obstacle, according to officials, is market demand. A rare virus that kills fewer people than other Ebola strains offers little financial incentive for manufacturers in wealthy countries to invest in prevention. Meanwhile, Africa manufactures almost none of its own vaccines or treatments. The continent's experience during the COVID-19 pandemic—watching wealthy nations hoard doses while African countries waited—spurred efforts to build local manufacturing capacity, but resources remain scarce and progress slow.
Africa CDC Director-General Jean Kaseya framed the problem bluntly: the continent cannot afford to depend on others to decide what gets made and when. "If we are serious in this continent, we need to manufacture what we need," he said. The current outbreak, spreading through a region already destabilized by conflict and migration, with a virus that has no cure and no prevention, is a test of whether that resolve can translate into action before the outbreak grows beyond containment.
Notable Quotes
There are significant uncertainties to the true number of infected persons and geographic spread associated with this event at the present time.— WHO Director-General Tedros Adhanom Ghebreyesus
If we are serious in this continent, we need to manufacture what we need. We cannot every single day look for others to come to tell us what they are doing.— Africa CDC Director-General Jean Kaseya
The Hearth Conversation Another angle on the story
Why did it take until May 5 to notice an outbreak that started in late April?
The first case appeared on April 24 in a remote area of Ituri province. By the time word reached health authorities through social media on May 5, fifty people had already died. The region is fractured by conflict and has limited surveillance infrastructure.
So the virus had a two-week head start.
Exactly. And in those two weeks, it moved through communities, crossed into Uganda, and eventually reached Kinshasa, the capital, 620 miles away. Slow detection gave it time to establish itself.
The WHO called it a global emergency, but also said it's not a pandemic. What's the difference?
A pandemic declaration would suggest uncontrolled spread across multiple continents. This is serious and spreading regionally, but not yet at that scale. The declaration is meant to spur action without triggering the kind of panic or border closures that can backfire.
What's the actual barrier to stopping it?
There's no vaccine and no approved treatment for this particular virus variant. But even if there were, Africa doesn't manufacture its own vaccines. It has to wait for wealthy countries to decide what's worth making.
Is this variant more or less dangerous than other Ebola strains?
Less deadly, actually. But that's part of the problem. Pharmaceutical companies see less financial incentive to develop treatments for a rarer, less lethal virus.
So the continent is trapped between a virus it can't treat and a global system that won't prioritize making the treatment.
That's the core of it. And in a region already destabilized by conflict and constant migration, that gap becomes catastrophic.